See more : Tactile Systems Technology, Inc. (TCMD) Income Statement Analysis – Financial Results
Complete financial analysis of Cyclerion Therapeutics, Inc. (CYCN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cyclerion Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Powerstorm Holdings, Inc. (PSTO) Income Statement Analysis – Financial Results
- LY Corporation (4689.T) Income Statement Analysis – Financial Results
- Graubündner Kantonalbank (0QLT.L) Income Statement Analysis – Financial Results
- Lite Access Technologies Inc. (LTE.V) Income Statement Analysis – Financial Results
- Axolot Solutions Holding AB (publ) (AXOLOT.ST) Income Statement Analysis – Financial Results
Cyclerion Therapeutics, Inc. (CYCN)
About Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 297.00K | 3.32M | 2.30M | 4.51M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 65.00K | 472.00K | 0.00 | 0.00 | 1.53M | 1.75M | 2.17M |
| Gross Profit | 0.00 | 232.00K | 2.85M | 2.30M | 4.51M | -1.53M | -1.75M | -2.17M |
| Gross Profit Ratio | 0.00% | 78.11% | 85.78% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.52M | 31.49M | 37.64M | 56.41M | 95.14M | 87.72M | 78.80M | 50.90M |
| General & Administrative | 8.13M | 14.50M | 20.62M | 28.82M | 34.40M | 27.54M | 15.12M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.13M | 14.50M | 20.62M | 28.82M | 34.40M | 27.54M | 15.12M | 10.48M |
| Other Expenses | 0.00 | -1.33M | -622.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.65M | 44.67M | 57.63M | 85.23M | 129.54M | 115.25M | 93.92M | 61.38M |
| Cost & Expenses | 9.65M | 44.67M | 57.63M | 85.23M | 129.54M | 115.25M | 93.92M | 63.55M |
| Interest Income | 358.00K | 294.00K | 0.00 | 588.00K | 2.03M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 294.00K | 16.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | -2.95M | 65.00K | 472.00K | 2.30M | 2.70M | 1.53M | 1.75M | 2.17M |
| EBITDA | -12.59M | -18.18M | -55.20M | -81.27M | -122.34M | -113.72M | -92.18M | -61.38M |
| EBITDA Ratio | 0.00% | -14,918.18% | -1,621.75% | -3,709.97% | -2,714.38% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.65M | -44.37M | -55.20M | -81.27M | -125.04M | -115.25M | -93.92M | -63.55M |
| Operating Income Ratio | 0.00% | -14,940.07% | -1,662.50% | -3,539.42% | -2,774.28% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.95M | 294.00K | 3.55M | 3.46M | 2.03M | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -12.59M | -44.08M | -51.65M | -77.80M | -123.01M | -115.25M | -93.92M | -63.55M |
| Income Before Tax Ratio | 0.00% | -14,841.08% | -1,555.63% | -3,388.59% | -2,729.27% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -294.00K | 16.00K | -5.13M | -2.03M | 1.37M | 0.00 | 0.00 |
| Net Income | -21.02M | -43.78M | -51.66M | -72.67M | -120.98M | -115.25M | -93.92M | -63.55M |
| Net Income Ratio | 0.00% | -14,742.09% | -1,556.11% | -3,165.07% | -2,684.25% | 0.00% | 0.00% | 0.00% |
| EPS | -8.99 | -20.15 | -26.40 | -47.80 | -88.37 | -84.42 | -68.80 | -46.39 |
| EPS Diluted | -8.99 | -20.15 | -26.40 | -47.80 | -88.37 | -84.42 | -68.80 | -46.39 |
| Weighted Avg Shares Out | 2.34M | 2.17M | 1.96M | 1.52M | 1.37M | 1.37M | 1.37M | 1.37M |
| Weighted Avg Shares Out (Dil) | 2.34M | 2.17M | 1.96M | 1.52M | 1.37M | 1.37M | 1.37M | 1.37M |
Regina Graul, Ph.D., Promoted to Chief Executive Officer
Cyclerion Appoints Regina Graul, Ph.D., as President
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates
Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies
Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium
Down 38.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Cyclerion Therapeutics, Inc. (CYCN)
Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders
Trending Penny Stocks to Buy Now? 5 to Watch This Week
Source: https://incomestatements.info
Category: Stock Reports